CIP2A nuclear-negative patients had a 5-year ovarian cancer-specific survival of 37.2% (95% CI 30.3–44.2), whereas it was 45.0% (95% CI 39.2–50.8) for those who showed nuclear positivity (P=0.013, log-rank test; Figure 2C). Here, CIP2A is linked to ovarian cancer.